menu
    • menu
    [{"orgOrder":0,"company":"Mosaic ImmunoEngineering","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"MIE-101","moa":"Toll-like receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Mosaic ImmunoEngineering","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Mosaic ImmunoEngineering \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Mosaic ImmunoEngineering \/ Inapplicable"},{"orgOrder":0,"company":"Mosaic ImmunoEngineering","sponsor":"University of California San Diego","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Licensing Agreement","leadProduct":"MIE-101","moa":"Toll-like receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Mosaic ImmunoEngineering","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Mosaic ImmunoEngineering \/ University of California San Diego","highestDevelopmentStatusID":"5","companyTruncated":"Mosaic ImmunoEngineering \/ University of California San Diego"}]

    Find Clinical Drug Pipeline Developments & Deals by Mosaic ImmunoEngineering

    Menu

    Mosaic ImmunoEngineering

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Mosaic ImmunoEngineering

                            U.S.A arrow
                            CRS
                            Not Confirmed

                            Mosaic ImmunoEngineering

                            U.S.A arrow
                            CRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MIE-101

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : University of California San Diego

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Mosaic ImmunoEngineering Expands Immuno-Oncology Platform Through New Technology Licensing Agreement with the ...

                            Details : Under the agreement, Mosaic has licensed rights to develop and commercialize new treatment candidates including lead product, MIE-101, is derived from the cowpea mosaic virus (CPMV), that broaden the scope and capabilities of the protein nanoparticle pla...

                            Product Name : MIE-101

                            Product Type : Microorganism

                            Upfront Cash : Undisclosed

                            June 10, 2021

                            Lead Product(s) : MIE-101

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : University of California San Diego

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Mosaic ImmunoEngineering

                            U.S.A arrow
                            CRS
                            Not Confirmed

                            Mosaic ImmunoEngineering

                            U.S.A arrow
                            CRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MIE-101

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Mosaic ImmunoEngineering's Lead Immuno-Oncology Candidate MIE-101 Highlighted in Keynote Presentation

                            Details : MIE-101, a Cowpea mosaic virus has shown to engage multiple Toll-like receptors on host immune cells in the tumor that have evolved to detect foreign invaders enhanced antitumor effects when combined with immune checkpoint inhibitors and other standard ...

                            Product Name : MIE-101

                            Product Type : Microorganism

                            Upfront Cash : Inapplicable

                            January 11, 2021

                            Lead Product(s) : MIE-101

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth